#Immunochromatography Kits Market Market Growth | Explore Tumblr posts and blogs

surajmarathedb1 · 2 years ago

Text

AFRICA POINT-OF-CARE DIAGNOSTICS MARKET Growth, Industry Size-Share, Global Trends, Key Players Strategies and Upcoming Demand

Data Bridge Market Research analyses that the AFRICA POINT-OF-CARE DIAGNOSTICS MARKET will project a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2022-2028.

A world class AFRICA POINT-OF-CARE DIAGNOSTICS MARKET research report is formulated with the finest and advanced tools of collecting, recording, estimating and analysing market data. With the systematic and comprehensive market research study, this market research report offers the facts associated with any subject in the field of marketing for Healthcare industry. It gives superior ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviours. This AFRICA POINT-OF-CARE DIAGNOSTICS MARKET report has been prepared by considering several fragments of the present and upcoming market scenario.

AFRICA POINT-OF-CARE DIAGNOSTICS MARKET Scope and Market Size

The Point-of-care diagnostics market is segmented on the basis of type, platform, end user and distribution channel.

On the basis of type, the Point-of-care diagnostics market is segmented into devices, software and services, consumables and kits, and accessories. In 2021, the devices segment in the point-of-care diagnostics market is expected to grow due to changing lifestyles and increasing chronic diseases, and a lack of awareness of over-the-counter point-of-care diagnostics devices.

On the basis of platform, the point-of-care diagnostics market is segmented into lateral flow assays (immunochromatography tests), dipsticks, microfluidics, molecular diagnostics, immunoassays. In 2021, the lateral flow assays/immunochromatography tests segment in the point-of-care diagnostics market is expected to grow due to advanced technologies and inventions.

On the basis of end user, the point-of-care diagnostics market is segmented into professional diagnostic centers, home care, research laboratories and other end users. In 2021, the professional diagnostic centers segment in the point-of-care diagnostics market is expected to grow due to growing patient emphasis on diagnosis operations. However, the high investment cost may hamper the Point-of-care diagnostics market growth.

Get the Free sample copy of the report here:

Some of the key questions answered in this report:

How has the AFRICA POINT-OF-CARE DIAGNOSTICS MARKET performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the AFRICA POINT-OF-CARE DIAGNOSTICS MARKET?

What are the key regional markets?

What are the key driving factors and challenges in the industry?

What is the structure of the AFRICA POINT-OF-CARE DIAGNOSTICS MARKET and who are the key players?

Market Analysis and Insights: AFRICA POINT-OF-CARE DIAGNOSTICS MARKET

The Point of care diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing at a CAGR of 5.7% in the forecast period of 2021 to 2028 and is expected to reach USD 816.12 million by 2028. Increasing prevalence of chronic diseases and rising preference for homecare testing are anticipated to drive the growth of the market.

The Point-of-care diagnostics is characterized as a testing which can be done in close proximity to the patient where a medical decision can be made immediately including the results and monitoring. Point-of-care diagnostics is also called with-patient testing and allows physicians to accurately measure real-time, lab-quality diagnostic results within less than minutes as compared to hours. It ensures patients to receive the most effective and efficient care when and wherever needed. Additionally, Point-of-care diagnostics enables staff to make rapid decisions of treatments when diagnosing patients’ condition and the Point-of-care diagnostics simplifying the testing process.

AFRICA POINT-OF-CARE DIAGNOSTICS MARKET - Regional Level Analysis

The countries covered in the point-of-care diagnostics market report are Kenya, Algeria, Nigeria, Morocco, Rwanda, Zambia, Uganda, Central African Republic, Chad, Ethiopia, Mauritania, Cameroon, Angola, Libya, DRC, Ghana, Malawi.

AFRICA POINT-OF-CARE DIAGNOSTICS MARKET - Share Analysis:

Point-of-care diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Point-of-care diagnostics market.

Key player - AFRICA POINT-OF-CARE DIAGNOSTICS MARKET

Some of the major players operating in the AFRICA POINT-OF-CARE DIAGNOSTICS MARKET are BioTech Africa, Medtronic, Bio-Rad Laboratories, Inc., PTS Diagnostics, Trinity Biotech, Atlas Medical Uk, Abbott, Sysmex Corporation, bioMérieux SA, Quidel Corporation, BD, Sekisui Diagnostics, F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., ACON Laboratories, Inc., Nova Biomedical, Siemens Healthcare S.A.E. (a subsidiary of Siemens Healthineers AG), Instrumentation Laboratory, Abaxis, and Radiometer Medical ApS (a subsidiary of Danaher) among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full Access of Report@

https://www.databridgemarketresearch.com/reports/africa-point-of-care-diagnostics-market MAJOR TOC OF THE REPORT

Chapter One: Introduction

Chapter Two: Scope and Market Size

Chapter Three: Analysis and Insights

Chapter Four: Country Level Analysis

Chapter Five: Share Analysis

Chapter Six: Key player

Get TOC Details:

https://www.databridgemarketresearch.com/toc/?dbmr=africa-point-of-care-diagnostics-market Top Trending Reports:

Global Autoclave Market

Global Proctoscope Market

Global Molecular Methods Market

Global Wound Debridement Market

Global Human Papilloma Virus Testing Market

Global Non-Small Cell Lung Cancer Market

Global CPAP Market

Global RNA Markers Market

Global Healthcare Cloud Computing Market

Global Medical Image Management Market

Global Pharmacogenetic Testing Market

Global Hemodialysis Services Market

Global Hemostatic Wound Dressing Market

Global Interventional Radiology Products Market

Global Lab Accessories Market

Global Label-free Array Systems Market

Global Laboratory Gas Generators Market

Global Life Science Analytics Market

Global Mediastinoscopes Market

Global Medical Alert System Market

Global EDS, WDS, EBSD, Micro-XRF Instruments Market

Global Direct-to-Consumer (DTC) Genetic Testing Market

Global Q- Polymerase Chain Reaction and D- Polymerase Chain Reaction Devices Market

Asia-Pacific (APAC) Q-PCR and D-PCR Devices Market

Europe Q-PCR and D-PCR Devices Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-386.8-2818

Email: [email protected]

0 notes

sanpdr1994 · 2 years ago

Text

Immunochromatography Kits Market 2022 Current Trends, Growth, Future Prospects 2032

According to Future Market Insights' most recent industry report, the Global Immunochromatography Kits Market is estimated to be valued at approximately US$ 8.1 Bn in 2022 and is expected to rise at a CAGR close to 4.1% over the forecast period, with an anticipated worth of around US$ 12.1 Bn in 2032.

The immunochromatography assay (ICA), also known as the lateral flow test, is a simple device that detects the presence or absence of a target analyte. Immuno-chromatography combines immunochemical reactions with chromatography, which is the separation of sample components based on changes in how they pass through a sorbent. The immunochromatography kits are the most widely used immunochromatography system.

The rising frequency of various infectious diseases is the main driver of the market for immunochromatography kits. Government attempts to improve healthcare systems by boosting the capacity of fast testing for initial screening and upgrading healthcare infrastructure are also a significant driver of market expansion. The market for immunochromatography kits is expanding due to rising consumer demand for easy-to-use home testing kits that can provide quick and precise results.

Globally, the market for immunochromatography kits is expanding as a result of an increase in the number of government-approved testing facilities and private points of care. Additionally, immunochromatography kits use cutting-edge technologies and are based on immunoassay or chromatography, which provides quick findings. Such rapid test kits are now much more in demand.

To stop the spread of COVID-19, governments in the majority of nations have instituted rigorous pathogen testing. Immunochromatography kits sales are likely to expand over the forecast period as medical companies, mostly diagnostic service providers, solidify their position within the industry.

Key Takeaways from Market Study

Kits are the leading segment as product, and hold approximately 72.7% market share in 2021. Growing demand for point-of-care diagnostic devices further compliments the market share for the kits segment, globally.

Infectious diseases, segmented by application, hold a market share of around 34.5% in 2021, owed to the advent of the COVID-19 pandemic, and the associated measures to prevent, detect, and manage infection proliferation.

By distribution channel, hospital pharmacies account for around 36.5% of the global market share in 2021, owing to the use of immunochromatography kits for rapid identification of pathogen for further disease monitoring in patients.

North America is considered as the leading region with a value US$ 3.2 Bn in 2021, owing to the high prevalence of disease and large demand for at-home testing kits.

“Rapidly ageing population, growing demand for point-of-need diagnostics, and rising government initiatives for infection prevention and control, are factors propelling demand within the global immunochromatography kits industry,” says an analyst of Future Market Insights.

Market Competition

Key competitors in the global immunochromatography kits market adopt several strategies for product development and its adoption, including receiving emergency use authorization by regulatory bodies. Moreover, with the threat of infection spread due to the global COVID-19 pandemic, several competitors have reflected the SARS-COV2 antigen detection within their product range.

Key developmental instances include:

Beckman Coulter Inc., a manufacturer of laboratory equipment for Danaher Corp., received emergency use approval from the US Food and Drug Administration in October 2020 for its COVID-19 antibody test.

BioMérieux announced in May 2022 that its automated tests for diagnosing Chikungunya virus (CHIKV) infection on immunoassay instruments from the VIDAS® line have received CE marking.

Key Market Segments Covered in Immunochromatography Kits Industry Research

By Product:

Readers

Kits

By Application:

Sexually Transmitted Diseases

Infectious Diseases

Diabetes

Pregnancy Testing

Drug of Abuse Testing

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Supermarket/Hypermarket

E-Commerce

By Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East and Africa (MEA)

#Immunochromatography Kits Market Market #Immunochromatography Kits Market Market Size #Immunochromatography Kits Market Market Growth

0 notes

researchvishal · 2 years ago

Text

Lateral Flow Assays Market Regional Outlook, Trends, Key Companies Profile, CAGR and Forecast to 2032

According to a recent lateral flow assays market report by Future Market Insights (FMI), the lateral flow assays market was valued at US$ 11 Bn in 2021, is projected to reach US$ 12.5 Bn by 2026, and is anticipated to grow at a CAGR of around 2% over the projected period of 2022-2032.

The high rate of infectious diseases around the world, explosive growth in the geriatric population, escalating demand for point-of-care testing, and increased use of home-based rapid lateral flow devices are all boosting lateral flow assays market forward. The significant restraints are doctors’ and patients’ reluctance to change existing diagnostic techniques and the low accuracy of lateral flow assays.

The affordable cost of lateral flow assays devices and the fact that no trained personnel is required to run the tests are two factors driving up demand for lateral flow assays-based devices for COVID-19 testing.

The growing adoption of kits & reagents due to innovations and benefits of lateral flow assays rapid tests over laboratory tests the high number of lateral flow assay rapid detection kits launched by healthcare companies, predominantly for lateral flow assay COVID-19 testing, are all factors contributing to the large share of the kits & reagents segment. Sandwich assays have a considerable part of the lateral flow assays market due to the growing use of sandwich assays in medical testing and the benefits of sandwich assays.

Despite the fact that lateral flow assay tests are simple to implement and less affordable than laboratory testing, they are less reliable. Due to the apparently limited accuracy of the lateral flow assay kit, most doctors and patients prefer molecular studies to fast tests for more accurate COVID-19 diagnosis. As a result, major diagnostic lateral flow assays market participants are concentrating their efforts on developing more laboratory-based infectious disease testing solutions.

Infectious disease lateral flow assays diagnostics, cardiac disease diagnosis, and veterinary applications are typical applications for lateral flow tests. However, the use of lateral flow technology has grown in various new applications in recent years. Potential applications for lateral flow tests include saliva diagnostics, behavioural health, agriculture (crop quality testing), biowarfare (anthrax detection), environmental testing, and food microbiology. Lateral flow assay (immunochromatography tests/lateral flow immunoassays) technologies continue to dominate the point of care diagnostic market through 2024.

The acquisition and validation of vital reagents are one of the most challenging elements of producing lateral flow assay tests. Antibodies used in assays must be evaluated for accuracy, specificity, stability, and reproducibility, as any reagent flaws can cause the lateral flow assay to fail. Another obstacle is lateral flow assays diagnostics after an antibody or antibody pair has been found.

Key Takeaways

The Kits & Reagents segment is anticipated to grow at a rapid CAGR of 5.3% during the forecast period.

The clinical testing segment accounted for 90.9% of the lateral flow tests market.

With a lateral flow tests market share of 70.9% in 2020, sandwich assays dominated the lateral flow tests market.

Blood samples were the most preferred, with a 53.1% lateral flow tests market share.

The hospitals and clinics segment was the most favoured, with a lateral flow tests market share of 37.6%.

China, the world’s second-largest economy, is expected to reach a lateral flow tests market size of US$917 million in 2027, with an annual growth rate of 8.8%.

Within Europe, Germany is expected to show a lateral flow tests market growth at a 4.8% compound annual growth rate (CAGR), while the rest of the European market will reach US$917 million by 2027.

The Asia Pacific region is expected to increase at a CAGR of 4.2% during the forecast period.

Get Sample PDF Brochure:

Competitive Landscape

Some companies have increased their lateral flow tests market share through various strategies such as mergers and acquisitions. In contrast, others invent new diagnostic market test methods and provide innovative goods to maintain their market share.

Key Segments

By Application:

Clinical Testing

Veterinary Diagnostics

Food Safety & Environmental Testing

Drug Development & Quality Testing

By Technique:

Sandwich Assays

Competitive Assays

Multiplex Detection Assays

By Sample Type:

Blood Samples

Urine Samples

Saliva Samples

Others

By Type

Kits & Reagents

Lateral Flow Readers

By End User:

Hospitals & Clinics

Diagnostics Laboratories

Home Care Settings

Pharmaceuticals & Biotechnology Companies

Others

0 notes

1market · 3 years ago

Text

Cardiac Biomarker Diagnostic Kits Market Market: Growth, Trends, Future Opportunities, Analysis and Forecast To 2025 |Research Informatic

Global Cardiac Biomarker Diagnostic Kits Market

Market Overview

Cardiac biomarkers like enzymes, hormones, and proteins are delivered into the blood in conditions when the heart is anxious or harmed. Cardiac biomarkers are utilized to assess the heart capacity of patients with chest torment and suspected intense coronary disorder. Cardiac Biomarker Diagnostic Kits assume a basic part in the early discovery or expectation of heart-related diseases.

In the emergency and the executives of the scope of heart-related conditions, Cardiac biomarkers are required, where time delay altogether affects the short and longer-term results of a patient. Conditions that can be analyzed incorporate myocardial localized necrosis, respiratory failure, intense coronary disorder, or ACS, among others.

Get Sample PDF Copy: https://www.researchinformatic.com/sample-request/205

Market Segmentation

The global Cardiac Biomarker Diagnostic Kits market can be segmented into Anatomy, Drug Type, Route of Administration, Purchasing Pattern, and Distribution Channel.

Based on type, the cardiac biomarkers market is segmented into

· Creatine kinase(CK-MB),

· Troponins T and I,

· Myoglobin,

· B-type natriuretic peptide (BNP),

· N-terminal prob-type natriuretic peptide (NT-proBNP),

· Ischemia-modified albumin (IMA), and others.

Based on product, the market is segmented into

· Reagents and Kits,

· Instruments,

· Chemiluminescence,

· Immunofluorescence,

· Elisa, and Immunochromatography.

Based on disease, the market is segmented into

· Myocardial Infarction,

· Congestive Heart Failure.

Based on testing type, the market is segmented into

· Laboratory Testing,

· Point-Of-Care Testing.

Check available discounts on this report: https://www.researchinformatic.com/discount-205

Regional Analysis

North America is anticipated to lead the market during the forecast period. The growth of the market can be attributed to the increasing number of obesity cases and the significant rise in obesity cases. According to United Nations World Population Ageing 2019 Report, in the United States, the number of people 65 years of age is expected to reach 70.842 million by 2032. Further, increasing research and development activities in the development of novel therapeutics in the North American region is projected to be another salient cause bolstering the industry in the forecast period. For instance, in March 2019, Fidia Pharma USA Inc. obtained FDA's approval for TRILURON, which is a hyaluronic acid (HA) based intra-articular viscosupplement indicated for the treatment of knee pain in Cardiac Biomarker Diagnostic Kits. Owing to the aforementioned factors, the market in North America is expected to lead the industry in the forecast period.

Do You Have Any Query or Specific Requirement? Ask Our Industry Expert: https://www.researchinformatic.com/inquiry/205

Competitive Landscape

Key players of the global Cardiac Biomarker Diagnostic Kits market include

· Beckman Coulter

· bioMérieux SA

· Philips

· Abbott Laboratories

· Olympus Corporation

· Siemens Healthcare GmbH

· Johnson and Johnson

· Hoffmann-La Roche Ltd.

· Tosoh Corporation

· PerkinElmer Inc.

Some of the recent developments are:

· In February 2020, Anika Therapeutics Inc. acquired Arthosurface, which resulted in the growth of the joint preservation and restoration product portfolio.

· In December 2020, Moebius Medical received FDA clearance for its investigational new drug application to start a global multi-center Phase LLB clinical trial of MM-II. It is a novel candidate for treatment for pain due to knee Cardiac Biomarker Diagnostic Kits.

Key Benefits of the report-:

1. Reveals insight into the restrictions present in the worldwide Cardiac Biomarker Diagnostic Kits Market that can hamper the development of the market in the coming years.

2. The report introduces a reasonable focus on how these limitations can be transformed into circumstances when surveyed appropriately.

3. Developing ways of life, tax collection arrangements, and buying forces of different economies have been examined in Cardiac Biomarker Diagnostic Kits Market incredible detail.

4. Displays generation and income estimates for the worldwide market, creation and utilization estimates for local needs, output, income, and value figures for the worldwide Cardiac Biomarker Diagnostic Kits Market.

5. Offers a forward-looking point of view of the Cardiac Biomarker Diagnostic Kits Market by giving nitty-gritty insights giving brisk data about the market's general advancement throughout the conjecture time frame.

6. Improves decision-making capabilities by presenting accurate to an extended picture of this vast Cardiac Biomarker Diagnostic Kits Market.

Get Your Customised Research Report: https://www.researchinformatic.com/request-customization-205

Some Points from Table of Contents of Global Cardiac Biomarker Diagnostic Kits Market:

Chapter 1 Cardiac Biomarker Diagnostic Kits Market Overview

1.1 Product Overview and Scope of Cardiac Biomarker Diagnostic Kits

1.2 Cardiac Biomarker Diagnostic Kits Market Segmentation By Type

1.2.1 Creatine Kinase (CK-MB),

1.2.2 Troponins T And I,

1.2.3 B-Type Natriuretic Peptide (BNP),

1.2.4 N-Terminal Prob-Type Natriuretic Peptide (NT-Probnp),

1.2.5 Ischemia-Modified Albumin (IMA)

1.3 Cardiac Biomarker Diagnostic Kits Market Segmentation by Applications

1.3.1 Reagents and Kits,

1.3.2 Instruments,

1.3.3 Chemiluminescence

1.3.4 Immunofluorescence,

1.3.5 Elisa, and Immunochromatography

1.4 Cardiac Biomarker Diagnostic Kits Market Segmentation by Regions

1.4.1 North America

1.4.2 China

1.4.3 Europe

1.4.4 Southeast Asia

1.4.5 Japan

1.4.6 India

1.5 Global Market Size (Value) of Cardiac Biomarker Diagnostic Kits (2015-2027)

Chapter 2 Global Economic Impact on Cardiac Biomarker Diagnostic Kits Industry

2.1 Global Macroeconomic Environment Analysis

2.1.1 Global Macroeconomic Analysis

2.1.2 Global Macroeconomic Environment Development Trend

2.2 Global Macroeconomic Environment Analysis by Regions

Chapter 3 Global Cardiac Biomarker Diagnostic Kits Market Competition by Manufacturers

TOC Continued……

Browse In-depth Research Informatic Report (250 Pages) on Cardiac Biomarker Diagnostic Kits Market @ https://www.researchinformatic.com/reports/cardiac-biomarker-diagnostic-kits-market/205

Check out more studies related Reports, published by Research Informatic:

· Animal Ultrasound Market Size, Share, Growth | Industry Forecast Report, 2026

· Health Data Archiving Market Size, Share, Growth | Industry Forecast Report, 2026

· DNA Origami Market Size, Share, Growth | Industry Forecast Report, 2026

About Us:

Research Informatic is a bulging market research and consultancy company based in Nevada, United States, with a report distribution center in India. We are committed to assisting our clients in making critical business decisions by fulfilling their niche market research needs. Our clients are spread across more than 130 countries and in all business domains. Our service offerings include syndicated research, tailored research, consumer surveys, and consulting. We concentrate on making investment decisions based on a variety of criteria such as growth size, benefits strategies, technical advances, and changing consumer inclinations, to name a few.

Our syndicated and custom research reports assist our customers in growing their businesses across a broad range of industries. In the fields of healthcare, chemicals and materials, ICT, Automation, Semiconductors & Electronics, Consumer goods, Energy, Food & Beverages, and Packaging, we include research studies in the form of syndicate reports, custom reports, market surveys, and consultancy projects.

Contact Us:

George Miller

1887 Whitney Mesa

Dr. Henderson, NV 89014

+1 775 237 4147

[email protected]

https://researchinformatic.com

Web: https://www.researchinformatic.com/categories/life-science

Follow us on LinkedIn:https://www.linkedin.com/company/research-informatic/mycompany/

Have a look at our Related Articles:

2.2 million Indian accounts Banned by What'sapp. - NUNewsIndustry

Wharton School Will Accept Cryptocurrency As Payment Method

Facebook is investing $150 million into virtual reality - NUNewsIndustry

Facebook rebrands itself to 'Meta' - NUNewsIndustry

Meta Plans to Launch Smartwatch With Camera - NUNewsIndustry

#Cardiac Biomarker Diagnostic Kits Market #Cardiac Biomarker Diagnostic Kits Market Share #Cardiac Biomarker Diagnostic Kits Market Future #Cardiac Biomarker Diagnostic Kits Market Growth #Cardiac Biomarker Diagnostic Kits Market Opportunity

0 notes

healthcare-market · 3 years ago

Text

Molecular Point-of-care Diagnostics Market : Global Forecast Over 2024

Point-of-care diagnosis involves medical tests performed at or near a patient’s location. These tests can be performed outside a clinical laboratory, and primarily include diagnosis done at physician’s office, in an ambulance, or on-field diagnosis. Molecular diagnosis involves analysis of biological markers and has wide applications in disease monitoring and testing, risk analysis, cancer diagnosis, and others. These tests were designed as physicians needed quick analysis of samples to diagnose diseases and avoid complications. Traditional microbial testing methods were non-specific, lengthy, and time consuming procedures. Molecular diagnostics have armed doctors with highly specific, quick, and accurate diagnosis methods. Presently, point-of-care testing has become an integral part of the diagnostics market, and widely used in emergency rooms, community health centers, school health programs, and home testing.

Read Report Overview: https://www.transparencymarketresearch.com/molecular-point-of-care-diagnostics-market.html

Based on application, the global molecular point-of-care diagnostics market can be segmented into infectious disease, oncology, autoimmune disease, hematology, and others. In terms of test location, the market can be categorized into point-of-care tests and over-the-counter tests. The global molecular point-of-care diagnostics market is driven by quick and accurate results, and ability to carry out tests without laboratory set-up. The market is also driven by consistent rise in emergency medical cases. The trend is also shifting from hospital testing to point-of-care testing, where patients can be diagnosed in shortest possible time, and also reduce hospital stay. Increase in awareness about diseases and available diagnosis and treatment methods has given rise to the concept of ‘preventive health care’, with patients being actively involved in disease diagnosis. In 2007, Clinical Laboratory Improvement Amendments (CLIA) waiver policies were modified stating that FDA approved tests for home use also qualify for CLIA waiver. This boosted the growth of the home diagnostics market which is dominated by immunochromatography based cassette kits. These trends coupled with advances in the biotechnology sector are likely to propel the molecular point-of-care diagnostics market. Growing burden of diabetes and infectious diseases such as tuberculosis, dengue, malaria, flu, and many other diseases have demanded better diagnosis services in short span of time such as molecular point-of-care diagnosis. Cases of drug abuse are also on the rise in the countries in the West. According to a survey conducted by the European Monitoring Centre for Drugs and Drug Addiction, Britain has the largest number of drug addicts in Europe. The survey also details that cannabis abuse is highest and cocaine abuse is rising rapidly. These incidences also support market growth.

Request a Sample of Molecular Point-of-care Diagnostics Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39317

Geographically, the global molecular point-of-care diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Majority of the molecular point-of-care diagnostics market is concentrated in North America and Europe owing to increase in demand for near patient testing and diagnosis of disease at molecular level. Asia Pacific is an emerging market and is expected to grow at a rapid pace during the forecast period due to increase in per capita income, vast population base, developing medical sector, and rise in trend for medical tourism. High cost of molecular point-of-care diagnostics and lack of awareness hamper the growth of the market in regions such as Latin America and Middle East & Africa.

Pre-book Molecular Point-of-care Diagnostics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=39317&ltype=S

Key players operating in the global molecular point-of-care diagnostics market include Abbott, F. Hoffmann-La Roche Ltd., bioMerieux, Danaher, DiaSorin, Sysmex, and Siemens Healthineers.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/topical-oral-medications-core-of-acne-scar-treatment-market-growth-trajectory--tmrs-study-301341979.html

https://www.prnewswire.com/news-releases/increase-in-focus-on-use-of-advanced-technology-for-drug-development-research-activities-to-drive-global-biosimulation-market-finds-tmr-301348168.html

https://www.prnewswire.com/news-releases/rise-in-use-of-technologically-advanced-products-in-orthopedic-disease-treatment-creates-lucrative-avenues-for-orthopedic-devices-market-opines-tmr-301355874.html

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

sapanas · 4 years ago

Text

Immunofluorescence Assay Market Growth Prospects, Key Opportunities, Trends, Forecasts, Key Company Profiles And Industry Size, Share Analysis

“The Latest Research Report Global Immunofluorescence Assay Market By 2023 provides information on Market Size, Analysis, Shares, Forecast, Emerging Technologies and Company Profiles for key Industry Participants – Market Research future”

Immunofluorescence Assay Market Overview

The global immunofluorescence assay market is growing pervasively. The market growth attributes to the increase in biological studies in R&D for the detection of biomolecules like glycans, proteins, and small biological and non-biological molecules of various diseases. Also, immunofluorescence assays are primarily used for rapid and sensitive diagnostics of various chronic diseases such as cancer, autoimmune diseases, infectious diseases like HIV, neurological disorders such as Alzheimer's and Parkinson's diseases.

With the intervention of the COVID-19, the immunofluorescence assay industry is witnessing a massive demand across the globe. This is due to the rising usages of immunofluorescence assays in the development of antibodies that can detect sars-Cov-2 in patient samples. According to Market Research Future (MRFR), the global immunofluorescence assay market is projected to register 5.8% CAGR during the analysis period (2017–2023).

Read more news on: https://www.medgadget.com/2020/06/covid-19-impacts-on-the-global-immunofluorescence-assay-market-2020-growth-industry-analysis-size-share-top-company-profile-regional-outlook-swot-analysis.html

Advancements in medical technology, alongside the increasing R&D funding by industry leaders and governments, boost the market growth. Additionally, rising numbers of preclinical research, alongside the rising studies on antibody therapies, advanced drug discoveries, and oncology diseases, accelerate the market growth. Growing collaborations between research institutes and biotechnology companies are expected to drive the growth of the immunofluorescence assay market.

Conversely, the high cost of immunofluorescence assay products such as diagnostic kits is expected to restrict the market growth during the forecast period. Also, factors such as risks of cross contaminations and shortage of skilled labor & weak detection signals are estimated to impede the growth of this market. Nevertheless, growing advancements in biotechnology & medical science would support the growth of the market, bringing about cost-effective immunofluorescence assay.

Global Immunofluorescence Assay Market – Segmentation

The Immunofluorescence Assay Market report is segmented into five dynamics;

By Technique: Primary (Direct) Immunofluorescence Assays and Secondary (Indirect) Immunofluorescence Assays (Salt split technique, Antigenic mapping method, Double Staining method), Micro Immunofluorescence.

By Product Type: Antibodies, Kits & Reagents, Instruments, Microscopes, Imaging Analysis Systems, Labeling dyes, Species Product Type, and others.

By Application: Clinical Research, Clinical Diagnostics, Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Neurological Diseases, Research & Development, and others.

By End-User: Biotechnology Companies, Hospitals & Research Institutes, Contract Research Organizations, Diagnostic centers, and others.

By Regions: Americas, Europe, Asia Pacific, and Rest-of-the-World.

Global Immunofluorescence Assay Market – Regional Analysis

North America dominates the global immunofluorescence assay market. The largest market share attributes to the high prevalence of chronic diseases and rising R&D investments within this region. Also, the rising adoption of advanced systems for early diagnosis of diseases drives the regional market growth. Moreover, the advancement in the development techniques and increasing use of nanotechnology in the development of immunofluorescence assay fostered the growth of the regional market.

The US, among other North American countries, holds the largest share in the regional market. Besides, the presence of vast numbers of biotechnology & pharmaceutical companies impacts the regional market growth positively. The North American immunofluorescence assay market is estimated to retain its leading position throughout the assessment period.

Europe stands second in the immunofluorescence assay market. The market is driven by the increasing prevalence of myriads of chronic diseases such as cancer and the rapidly growing biotechnology sector in Europe. Moreover, substantial R&D investments by the public and private sectors, alongside the increasing R & D in biotechnology, foster the market growth in the region. The European immunofluorescence assay market is projected to create a substantial revenue pocket over the review period.

The immunofluorescence assay market in the Asia Pacific region is growing rapidly. Factors such as the growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure, and increasing R&D activities in the biotechnology sector influence the market in this region. Also, the presence of major market players in China, India, and Japan drive market growth. Rising government initiatives increase the size of the immunofluorescence assay market in the region.

The region witnesses rising developments of immunofluorescence assay products, while several products are under the pipeline, which is carried out under license agreements. The APAC immunofluorescence assay market is expected to grow at an impressive CAGR during the predicted period.

Global Immunofluorescence Assay Market – Competitive Analysis

Highly competitive, the global immunofluorescence assay market appears fragmented due to the presence of several well-established players. To gain a larger competitive advantage, players incorporate strategies such as mergers & acquisitions, collaborations, expansion, and product/technology launch. Top players make huge investments for R&D and clinical trials to develop these assays. Pharmaceutical companies are the largest investors in the immunofluorescence assay market.

Immunofluorescence Assay Market Major Players:

Players leading the global immunofluorescence assay market include Abcam plc., Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc., BioTek Instruments, Inc., Bio-Rad Laboratories, Inc., Zyagen Cell Signaling Technology, Inc., PerkinElmer Inc., Becton Dickinson and Company, Merck, Agilent Technologies, TCS Biosciences Ltd, and Maxvision Biosciences Inc., among others.

Immunofluorescence Assay Industry/Innovation/ Related News:

May 29, 2020 --- Rockland Immunochemicals Inc. (the US), a leading global biotechnology company, announced the development of a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19. The antibody specifically reacts with the SARS-CoV-2 Nucleocapsid protein present in patient samples and has shown in various independent testing laboratories in regions highly specific and sensitive for SARS-CoV-2.

Rockland manufactures tools for basic, applied, and clinical research in functional genomics, gene therapy, and drug discovery markets. It offers each academic, biopharma, and professional diagnostic thousands of antibodies to provide the right antibody that is the perfect fit for every occasion. The newly developed antibody has proven effective in lateral flow assays (immunochromatography), ELISA, Western blotting, Immunofluorescence microscopy, fluorescence-activated cell sorting, and immunohistochemistry.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/immunofluorescence-assay-market-6177

#Immunofluorescence Assay Market #Immunofluorescence Assay Market Size #Immunofluorescence Assay Market Share #Immunofluorescence Assay Market Growth #Immunofluorescence Assay Market Analysis #Immunofluorescence Assay Market Trends

0 notes

sumit76652-blog · 6 years ago

Text

Cardiac Marker Testing Devices Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis, 2018-2026

Cardiac markers are diagnostic tool, which are associated for diagnosis and risk detection in patients suffering from chest pain, acute coronary syndrome (ACS), and acute myocardial infraction (MI). Cardiac marker test detects the endogenous substances, which are released during the blood circulation mainly when the heart is damaged or stressed, thereby, assessing risk and directing appropriate therapy that improves clinical outcome in high-risk patients. Cardiac markers are used in hospitals to either detect cardiac injury or to evaluate future risk of cardiovascular disease.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1039

Myoglobin, homocysteine, troponin T (cTnT), troponin I (cTnl), creatine kinase-MB (CK-MB), and C-reactive protein (CRP) are cardiac markers used for assessment of acute myocardial infraction. However, CK-MB, cTnl, and cTnT are used to identify and manage acute coronary syndrome in high-risk patients. Cardiac troponin I and T are most preferred and extensively used cardiac marker for myocardial injury, due to their higher sensitivity and specificity for diagnosis of myocardial infraction.

According to Journal of the American Medical Association (JAMA), in 2016, acute coronary syndrome is estimated as the major cause of morbidity and mortality worldwide. It is also responsible for over 1 million hospital admissions in the U.S. annually. Increasing incidence of myocardial infraction (MI) or heart attack, acute coronary syndrome, and consistent development in cardiac markers by existing market players are some of the factors fueling growth of the cardiac marker testing devices market. Moreover, high blood pressure, high LDL cholesterol, smoking, unhealthy diet, diabetes, obesity, physical inactivity, and excessive alcohol consumption are some other factors which cause coronary heart disease and associated disorders. This in turn, is expected to drive growth of the global cardiac marker testing devices market in the near future.

According to a report by National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), in 2016, around 47% of geriatric population in U.S. have at least one of three major risk factor of cardiovascular disease (CVD), which includes uncontrolled high blood pressure, uncontrolled high LDL cholesterol, and smoking. However, controlling these factors could reduce the risk of heart attack by 80%. BBI Solutions- a developer and manufacturer of raw material and finished test platforms for the in-vitro diagnostic tests, in 2017 announced to launch myoglobin antibiotics as a cardiac marker. These cardiac marker have been tested in ELISA assay before using it in commercial assay procedures and patient’s screening processes. The launch of new cardiac marker allows expansion of BBI solution’s antibodies portfolio in the global cardiac marker testing devices market.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cardiac-marker-testing-devices-market-1039

According to American Heart Association (AHA), around 790,000 people in U.S. have heart attack every year. Furthermore, an estimated annual incidence of heart attack in the U.S. are around 580,000 cases and 210,000 recurrent cases. According to AHA 2017 report, myocardial infraction diagnosis cost around US$ 11.5 billion and coronary heart disease cost around US$ 10.4 billion, were estimated as the most expensive hospital discharge diagnosis. The number of cardiovascular disease cases is expected to increase to 131.2 million by 2035, accounting to nearly 45% of the total U.S. population, with expected cost to reach US$ 1.1 trillion, which in turn, is expected to drive growth of the cardiac marker testing devices market.

Cardiac Marker Testing Devices Market Taxonomy:

By marker type:

Lactate Dehydrogenase

Creatine Kinase (CK)

CK-MM

CK-MB

CK-BB

Myoglobin

Natriuretic Peptides

Aspartate Aminotransferase (AST)

Cardiac Troponin

C-reactive Proteins

Others (galectin-3, myeloperoxidase, homocysteine, H-FABP, and ischemia-modified albumin)

By product type:

Instruments

Chemiluminescence

Immunofluorescence

Immunochromatography

ELISA

Reagents and kits

By application:

Acute Coronary Syndrome (ACS)

Myocardial Infraction (MI)

Cardiac Heart Failure

Others

By testing type:

Laboratory testing

Pont-of-care testing

By end user:

Hospitals

Diagnostic Laboratory

Home care setting

Major acquisitions are expected to drive growth of the cardiac marker testing devices market

In 2017, U.S. Federal Trade Commission (FTC) allowed US$ 5.3 billion of acquisition of Alere’s point-of-care cardiac marker testing business to Abbott Laboratories. The deal between Abbott Laboratories and Alere created the world’s largest point-of-care testing business, which significantly strengthen and grow Abbott’s diagnostic presence in cardiac marker testing devices market.

Moreover, in 2017, FTC approved the deal of Alere’s Triage B-type Naturietic Peptide (BNP) assay business and Triage MeterPro toxicology and cardiovascular business with Quidel Corporation. The acquisition of Alere’s point-of-care cardiac marker testing business is expected to improve Quidel’s portfolio of rapid diagnostic testing solutions.

Key players in the cardiac marker testing devices market

Some of the key players operating in the global cardiac marker testing devices market are Bio-Rad Laboratories, Inc., Siemens Medical Solutions USA, Inc., Randox Laboratories Ltd., Abbott Laboratories, Becton, Dickinson and Company, Helomics Corp., LSI Medience Corporation, F.Hoffmann-La Roche Ltd., Enzo Biochem Inc., Ortho Clinical Diagnostics, Danaher Corporation, and bioMerieux SA.

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1039

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

0 notes

shristipbi · 5 years ago

Text

Congestive Heart Disease Marker Tests Market Growth, Market Insights and Forecast to 2025

The global congestive heart disease marker tests market expected to reach US$ 4,326.8 Mn by 2025 owing to rise in prevalence of various cardiac diseases around the globe. For instance, according to World Health Organization, approximately 17.9 Mn deaths occurring due to cardiovascular diseases each year around the globe. Moreover, screening programs organized by government to increase the awareness about the cardiac diseases among the population, increase in the R&D investment for the development of innovative diagnostic tests, and sophisticated healthcare infrastructure in developing and developed countries are anticipated to propel the congestive heart disease marker tests market over the forecast years. However, high cost for the diagnostic tests, lack of advanced diagnostic techniques in low income countries, and stringent regulations for the test approval, are deter the congestive heart disease marker tests market over the forecast timeframe

Global congestive heart disease marker tests market segmented on the basis of product type, technology, test type, application, end user, and region

For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15832

Troponins Test Segment Dominate the Global Congestive Heart Disease Marker Tests Market

Based on the test type, global congestive heart disease marker tests market segmented into myocardial muscle creatine kinase, myoglobin, troponins (T and I), ischemia modified albumin, NT-proBNP, and others. Among all the tests, troponin (T and I) segment dominated the global congestive heart disease marker tests market and the same trend is expected over the forecast years owing to high efficiency and accuracy of troponin test results compared with other diagnostic tests. Moreover, launch of advanced diagnostic tests such as point-of-care devices also boost the market over the forecast years. For instance, in June 2015, Roche launched CARDIAC point-of-care Troponin T test for the cobas h 232 system to diagnose the heart attack in patients.

North America Leads the Global Congestive Heart Disease Marker Tests market

PBI’s global Congestive Heart Disease Marker Tests market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing increase in the prevalence of cardiac diseases in U.S. and Canada. For instance, according to American college of cardiology 2017, approximately 790,000 adults suffers from heart attack each year. Moreover, favorable reimbursement policies, increase in healthcare expenditure and presence of skilled professionals are bolster the market over the forecast years. Europe congestive heart disease marker tests market projected to exhibit significant growth due to adoption of technologically advanced diagnostic tests, rapid economic growth, and increase in healthcare expenditure are bolster the market

Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market player

Global Congestive Heart Disease Marker Tests market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In March 2017, Fujirebio Europe launched Lumipulse G hs Troponin I assay for use in the diagnosis of Acute Myocardial Infarction that provide precise and sensitive results in 35 minutes.

Key player’s profiles in the report are Bio-Rad Laboratories, Inc., Siemens Healthineers, Roche Diagnostics, Fujirebio Europe, Becton, Dickinson and Company, Randox Laboratories Ltd., BioMerieux, Thermo Fisher Scientific, and Beckman Coulter

Precision Business Insights (PBI) in its report titled “Global Congestive Heart Disease Marker Tests Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period

Detailed Segmentation

By Products

o Reagents and Kits

o Instruments

o Software and Services

By Technology

o Chemiluminescence

o Immunofluorescence

o ELISA

o Immunochromatography

o Others

By Test Type

o Myocardial muscle Creatine Kinase (CK-MB)

o Myoglobin

o Troponins (T and I)

o Ischemia Modified Albumin (IMA)

o NT-proBNP or Brain Natriuretic Peptide (BNP) or

o Others

By Application

o Myocardial Infarction

o Acute Coronary Syndrome

o Congestive Heart Failure

o Atherosclerosis

o Others

By End User

o Hospitals

o Clinics

o Diagnostic Centers

o Others

Geography

o North America

· U.S

· Canada

o Europe

· Germany

· France

· U.K

· Italy

· Spain

· Russia

· Poland

· Rest of Europe

o Asia-Pacific

· Japan

· China

· India

· Australia & New Zealand

· ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)

· South Korea

· Rest of Asia-Pacific

o Latin America

· Brazil

· Mexico

· Argentina

· Venezuela

· Rest of Latin America

o Middle East and Africa (MEA)

· Gulf Cooperation Council (GCC) Countries

· Israel

· South Africa

· Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-congestive-heart-disease-marker-tests-market/

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: [email protected]

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

0 notes

ishwetu · 6 years ago

Text

Point Of Care/POC/Rapid Diagnostics Market - Global Opportunity Analysis And Industry Forecast (2018 – 2024)

A report into the projected growth of the current point of care (POC) diagnostics market by Meticulous Research® has produced some incredible forecasts for the industry. By 2024, it’s expected to have grown at a CAGR of 8%, reaching $30.9 billion.

Future Outlook: Point of Care (POC) Diagnostics Market to Offer Significant Growth Opportunities

In a report published today, Meticulous Research® has stated that the size of the global point of care diagnostics market will reach an impressive $30.9 billion by 2024.

The researchers predict that significant growth will be driven by variety of factors including growing incidence of target diseases such as cancer, diabetes, cardiovascular diseases, and infectious diseases; the need for rapid results in certain medical situations; increasing usage of home-based tests/self-testing; rising number of CLIA-waived product approvals; and increasing funding/investment for the development of POC products.

Browse in-depth Report on: https://www.meticulousresearch.com/product/point-of-care-diagnostics-poc-market

The report states that lateral flow assays (immunochromatography tests/lateral flow immunoassays) platform accounts for the largest share of the total market. However, point-of-care molecular diagnostics tests are expected to grow at a fastest CAGR of 13.3% from 2018 to 2024. Meticulous Research® anticipated as to why this area is emerging as the largest use of the platform: “The shift from the traditional microbiology-based testing to molecular testing stems from the rising antibiotic resistance crisis, and faster turnaround time of POC molecular assay tests.”

Over-the-Counter (OTC) testing is cited as the major trend driving the growth of point of care diagnostics market. OTC testing kits are expected to generate relatively higher revenue than prescription tests over the forecast period owing to the associated ease of usage, growing home care and self-testing, and higher availability and greater adoption rate.

On the basis of product type, blood glucose monitoring testing currently dominates the global POC diagnostics market; however, infectious diseases testing kits segment is expected to register growth during the forecast period. Influenza causes 12,000- 50,000 deaths annually in the U.S. Rapid testing for influenza A and B allows for accurate and timely treatment, as patients only have a 48-hour window to receive critical antiviral therapy. Thus, growing prevalence of infectious diseases and need for rapid testing and treatment provide robust opportunities for POC testing companies like BD, Quidel, Roche, and Alere (Abbott). Meticulous Research® help companies operating in POC market to identify key growth segments to invest in.

Finally, the report states that North America is currently the home of most of the point of care diagnostics companies. However, Asia-Pacific is named as the area expected to grow most by 2024. Major reasons cited for this rising demand include accelerated growth of the economies; relatively lower availability of sophisticated central laboratory testing services; a larger population base in need for clinical testing; increasing incidence of infectious and non-communicable diseases in aging population; and improving availability and awareness of POC tests.

Download Research Sample Report: https://meticulousresearch.com/download-sample-report/cp_id=4871

The key players operating in the global point of care diagnostics market are Abbott Laboratories, AccuBioTech Co., Ltd., Becton Dickinson and Company, Chembio Diagnostic Systems, Inc., Danaher Corporation, EKF Diagnostics Holdings plc, WerfenLife, S.A., Johnson and Johnson Service, Inc., Nova Biomedical, F. Hoffmann-La Roche Ltd, Sekisui Diagnostics LLC, Quidel Corporation, Siemens AG, and Trinity Biotech, among others.

Contact Us:

Meticulous Research

Email- [email protected]

Contact Sales- +1-646-781-8004

#medical devices #healthacare research